Page last updated: 2024-08-23

acetylgalactosamine and Cardiovascular Diseases

acetylgalactosamine has been researched along with Cardiovascular Diseases in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Biessen, EAL; Van Berkel, TJC	1
Aretz, J; Campion, G; Chivers, S; Eisermann, M; Hauptmann, J; Löffler, K; Morrison, E; Rider, D	1
Akinkuolie, AO; Buring, JE; Chandler, PD; Glynn, RJ; Lawler, PR; Lee, IM; Moorthy, MV; Mora, S; Ridker, PM; Schaumberg, DA; Vandenburgh, MJ	1

Reviews

1 review(s) available for acetylgalactosamine and Cardiovascular Diseases

Article	Year
N-Acetyl Galactosamine Targeting: Paving the Way for Clinical Application of Nucleotide Medicines in Cardiovascular Diseases. Arteriosclerosis, thrombosis, and vascular biology, 2021, Volume: 41, Issue:12 Topics: Acetylgalactosamine; Cardiovascular Diseases; Drug Delivery Systems; Genetic Therapy; Hepatocytes; Humans; Liver; Oligonucleotides; RNAi Therapeutics	2021

Other Studies

2 other study(ies) available for acetylgalactosamine and Cardiovascular Diseases

Article	Year
Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease. Toxicological sciences : an official journal of the Society of Toxicology, 2022, 09-24, Volume: 189, Issue:2 Topics: Acetylgalactosamine; Alanine Transaminase; Alkaline Phosphatase; Animals; Cardiovascular Diseases; Cytokines; Ethers; Humans; Lipoprotein(a); Macaca fascicularis; Rabbits; Rats; RNA, Messenger; RNA, Small Interfering	2022
Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk. Circulation research, 2016, Apr-01, Volume: 118, Issue:7 Topics: Acetylgalactosamine; Acetylglucosamine; Acute-Phase Proteins; Aged; Biomarkers; Blood Proteins; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Polysaccharides; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Risk	2016

Article

Year

Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease.

Toxicological sciences : an official journal of the Society of Toxicology, 2022, 09-24, Volume: 189, Issue:2

Topics: Acetylgalactosamine; Alanine Transaminase; Alkaline Phosphatase; Animals; Cardiovascular Diseases; Cytokines; Ethers; Humans; Lipoprotein(a); Macaca fascicularis; Rabbits; Rats; RNA, Messenger; RNA, Small Interfering

2022

Circulating N-Linked Glycoprotein Acetyls and Longitudinal Mortality Risk.

Circulation research, 2016, Apr-01, Volume: 118, Issue:7

Topics: Acetylgalactosamine; Acetylglucosamine; Acute-Phase Proteins; Aged; Biomarkers; Blood Proteins; C-Reactive Protein; Cardiovascular Diseases; Cause of Death; Female; Follow-Up Studies; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Kaplan-Meier Estimate; Lipids; Male; Middle Aged; Mortality; Neoplasms; Nuclear Magnetic Resonance, Biomolecular; Polysaccharides; Proportional Hazards Models; Randomized Controlled Trials as Topic; Reproducibility of Results; Retrospective Studies; Risk

2016